A superior preparation method for daidzein-hydroxypropyl-β-cyclodextrin complexes with improved solubility and dissolution: Supercritical fluid process

1. S. Soumyakrishnan, T. Divya, S. Kalayarasan, N. Sriram and G. Sudhandiran, Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFbeta1/ Smad mediated inflammation and apoptosis in Bleomycin-induced experimental pulmonary fibrosis, Biochimie 103 (2014) 23-36; DOI: 10.1016/j.biochi.2014.04.005.10.1016/j.biochi.2014.04.00524769130Search in Google Scholar

2. B. Pahari, B. Sengupta, S. Chakraborty, B. Thomas, D. McGowan and P. K. Sengupta, Contrasting binding of fisetin and daidzein in gamma-cyclodextrin nanocavity, J. Photochem. Photobiol. B. 118 (2013) 33-41; DOI: 10.1016/j.jphotobiol.2012.10.010.10.1016/j.jphotobiol.2012.10.010355358923177044Search in Google Scholar

3. X. Dong, W. Xu, R. A. Sikes and C. Wu, Combination of low dose of genistein and daidzein has synergistic preventive effects on isogenic human prostate cancer cells when compared with individual soy isoflavone, Food. Chem. 141 (2013) 1923-1933; DOI: 10.1016/j.foodchem.2013.04.109.10.1016/j.foodchem.2013.04.10923870911Search in Google Scholar

4. H. J. Park, Y. K. Jeon, D. H. You and M. J. Nam, Daidzein causes cytochrome c-mediated apoptosis via the Bcl-2 family in human hepatic cancer cells, Food. Chem. Toxicol. 60 (2013) 542-549; DOI: 10.1016/j.fct.2013.08.022.10.1016/j.fct.2013.08.02223959101Search in Google Scholar

5. B. S. Pan, Y. Y. Kuo, T. Y. Chen and Y. C. Liu, Anti-oxidative and anti-inflammatory activities of two different species of a Chinese herb I-Tiao-Gung, Life Sci. 77 (2005) 2830-2839; DOI: 10.1016/j. lfs.2005.05.027.Search in Google Scholar

6. M. H. Park, J. W. Ju, M. J. Park and J. S. Han, Daidzein inhibits carbohydrate digestive enzymes in vitro and alleviates postprandial hyperglycemia in diabetic mice, Eur. J.Pharmacol. 712 (2013) 48-52; DOI: 10.1016/j.ejphar.2013.04.047.10.1016/j.ejphar.2013.04.04723669248Search in Google Scholar

7. H. J. Oh, Y. G. Kang, T. Y. Na, H. J. Kim, J. S. Park, W. J. Cho and M. O. Lee, Identification of daidzein as a ligand of retinoic acid receptor that suppresses expression of matrix metalloproteinase-9 in HaCaT cells, Mol. Cell. Endocrin. 376 (2013) 107-113; DOI: 10.1016/j.mce.2013.06.015.10.1016/j.mce.2013.06.01523791815Search in Google Scholar

8. Y. Ma, X. Zhao, J. Li and Q. Shen, The comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability, Int. J. Nanomed. 7 (2012) 559-570; DOI: 10.2147/IJN.S27641.10.2147/IJN.S27641327743622346351Search in Google Scholar

9. T. Loftsson and D. Duchêne, Cyclodextrins and their pharmaceutical applications, Int. J. Pharm. 329 (2007) 1-11; DOI: 10.1016/j.ijpharm.2006.10.044.10.1016/j.ijpharm.2006.10.04417137734Search in Google Scholar

10. T. Loftsson and M. E. Brewster, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci. 85 (1996) 1017-1025; DOI: 10.1021/js950534b.10.1021/js950534b8897265Search in Google Scholar

11. F. K. Yatsu, L. S. Koester, I. Lula, J. J. Passos and R. Sinisterra, Multiple complexation of cyclodextrin with soy isoflavones present in an enriched fraction, Carbohyd. Polym. 98 (2013) 726-735; DOI: 10.1016/j.carbpol.2013.06.062.10.1016/j.carbpol.2013.06.06223987405Search in Google Scholar

12. F. K. Yatsu, L. S. Koester, I. Lula, J. J. Passos, R. Sinisterra and V. L. Bassani, Cyclodextrin-based pharmaceutics: past, present and future, Nat. Rev. Drug. Discov. 3 (2004) 1023-1035; DOI: 10.1038/ nrd1576.10.1038/nrd157615573101Search in Google Scholar

13. S. W. Jun, M. S. Kim, J. S. Kim, H. J. Park, S. Lee, J. S. Woo and S. J. Hwang, Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process, Eur. J. Pharm. Biopharm. 66 (2007) 413-421; DOI: 10.1016/j. ejpb.2006.11.013.Search in Google Scholar

14. Q. L. Zhu, T. Guo, D. N. Xia, X. Y. Li, C. L. Zhu, H. Y. Li, D. F. Ouyang, J. W. Zhang and Y. Gan, Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration, J. Pharm. Pharmacol. 65 (2013) 1107-1117; DOI: 10.1111/jphp.12074.10.1111/jphp.1207423837579Search in Google Scholar

15. Q. L. Zhu, X. Y. Li, D. N. Xia, H. Z. Yu, D. Chen, W. W. Fan and Y. Gan, Lipid-based formulations for oral drug delivery: effects on drug absorption and metabolism, Curr. Drug. Metab. 16 (2015) 200-210; DOI: 10.2174/138920021603150812121453.10.2174/13892002160315081212145326279327Search in Google Scholar

16. L. M. Ensign, C. Richard and H. Justin, Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers, Adv. Drug Deliv. Rev. 64 (2012) 557-570; DOI: 10.1016/j.addr.2011.12.009. 10.1016/j.addr.2011.12.009332227122212900Search in Google Scholar